• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TOP
Click for more information
0.78% 65.0¢

THORNEY OPPORTUNITIES LTD

Market Cap $120.2M  ! watchlist Created with Sketch. Add to my watchlist

Thorney Opportunities Ltd is an Australia-based investment company. The Company’s... Thorney Opportunities Ltd is an Australia-based investment company. The Company’s principal activity is making investments in listed and unlisted securities in a variety of sectors, including media, automotive, energy, engineering and mining services and financial services. The Company’s investment objective is to produce absolute returns for shareholders over the medium to long term, through the selection of investments, which enables it to be a constructive catalyst towards unlocking the value in the companies identified. Its investment objective also includes delivering a fully franked dividend stream to shareholders. The Company is managed by Thorney Investment Group.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
TOP
Ann: Update - Notification of buy-back - TOP 		19/09/24 0 1
19/09/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  1 
TOP
Ann: Appendix 4G 		19/09/24 0 1
19/09/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  1 
TOP
Ann: Change in substantial holding for SSM 		25/03/19 0 77
25/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  77 
TOP
Ann: Change of Director's Interest Notice - A Waislitz 		25/03/19 0 70
25/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  70 
TOP
Ann: Change in substantial holding for TPE 		22/03/19 0 118
22/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  118 
TOP
Ann: Chairman's Update, March 2019 		22/03/19 0 122
22/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  122 
TOP
Ann: Change of Director's Interest Notice - A Waislitz 		22/03/19 1 163
22/03/19 Last post  Tinwins Comments Created with Sketch.  1  Views Created with Sketch.  163 
TOP
Ann: Change of Director's Interest Notice - A Waislitz 		12/03/19 0 113
12/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  113 

See All Discussions arrow Created with Sketch.

Timeline

Update - Notification of buy-back - TOP
19 Sep 09:00
 
Appendix 4G
19 Sep 09:00
 
(20min delay)
Last
65.0¢ 		Change
0.005(0.78%) 		Mkt cap ! $120.2M
Open High Low Value Volume
65.0¢ 65.5¢ 65.0¢ $145.4K 223.6K

Buyers (Bids)

No. Vol. Price($)
3 60905 63.0¢
 

Sellers (Offers)

Price($) Vol. No.
65.5¢ 95100 1
View Market Depth
Last trade - 15.32pm 15/11/2024 (20 minute delay) ?
Last
65.0¢ 		  Change
0.005 ( 0.78 %)
Open High Low Volume
65.0¢ 65.0¢ 65.0¢ 1203
Last updated 15.01pm 15/11/2024 ?
TOP (ASX) Chart

Top Stories

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.